BATF3 Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BATF3 gene in the CAL-27 human tongue squamous cell carcinoma cell line. This polyclonal pool enables loss-of-function studies without clonal selection, providing a heterogeneous model for investigating BATF3-dependent processes. The CRISPR-mediated disruption generates a mixed population of edited alleles, reflecting varied knockout efficiencies and phenotypes.
CAL-27 cells, derived from a primary tongue squamous cell carcinoma of a 56-year-old male, serve as a well-established model for oral squamous cell carcinoma. These epithelial cells maintain key characteristics of the tumor microenvironment, including aberrant signaling networks and invasive properties, making them suitable for studying oncogenic mechanisms and therapeutic responses in head and neck cancers.
BATF3 belongs to the AP-1 superfamily of basic leucine zipper transcription factors and functions as a critical regulator of CD8+ dendritic cell development and cross-presentation. It forms heterodimers with JUN, MAF, FOS, or IRF4 to modulate gene expression. Upstream, FLT3L and GM-CSF signaling through TLR pathways??involving TLR4, MyD88, NF-??B, and IRF8??drive BATF3 expression. BATF3, in turn, transcriptionally regulates downstream targets such as ID2 and IRF8, facilitating dendritic cell differentiation and immune response regulation. In the context of cancer, BATF3 influences tumor immunity and may intersect with interferon regulatory factor signaling and Th2 cell differentiation pathways.
In CAL-27 oral cancer cells, CRISPR/Cas9-mediated disruption of BATF3 alters transcriptional programs potentially governing cell cycle progression, apoptosis, and expression of immune regulatory genes. This knockout model allows dissection of BATF3’s tumor-intrinsic roles in oral squamous cell carcinoma, independent of its immune-cell functions. By uncoupling BATF3 activity from its canonical dendritic cell role, researchers can investigate how its loss affects epithelial tumor behavior, including proliferation, migration, and interactions with the immune microenvironment. This system is valuable for exploring BATF3-related pathways in oral carcinogenesis and for identifying novel vulnerabilities in head and neck cancers.
This polyclonal knockout cell pool is suited for a broad range of assays, including RNA-seq to profile transcriptomic changes, Western blotting and RT-qPCR for expression analysis, and cell proliferation, migration, invasion, and apoptosis assays to assess phenotypic consequences. Co-culture with immune cells enables study of tumor-immune crosstalk, while immunofluorescence can visualize BATF3-dependent protein localization. The model supports drug response assays and screening for compounds targeting BATF3-regulated pathways. It also aids in investigating dendritic cell-based therapy implications in oral cancer. For additional information or technical support, please contact Ascent Research.
